Tango Therapeutics, Inc. (TNGX) Tops Q2 EPS by 10c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q2 EPS of ($0.23), $0.10 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $7.19 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial
• Tango Therapeutics Appoints Robert Azelby to Board of Directors